ArticleJournal of ovarian research2026
A lactylation-related transcriptional signature as candidate biomarkers for the early detection of polycystic ovary syndrome: an integrated genomic analysis.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPolycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder that negatively impacts women's reproductive and metabolic health, leading to complications such as irregular menstruation, infertility, obesity, and metabolic syndrome. Current diagnostic methods, which primarily rely on clinical symptoms and hormone levels, lack specificity in early detection. This study aimed to identify lactylation-related transcriptional signatures as candidate biomarkers for the early detection of PCOS.
methodsWe conducted a comprehensive bioinformatic analysis using transcriptomic data from granulosa cells of PCOS patients in the GEO database. Patients were categorized into two molecular subtypes via consensus clustering based on the expression of lactylation-related genes. Subsequently, diagnostic models were constructed and validated to evaluate the potential of these transcriptional signatures as early diagnostic markers. External validation was performed using an independent dataset, and selected candidate genes were further examined in DHEA-treated KGN cells.
resultsWe identified nine key genes (HK3, SDC3, TGFBI, ZYX, LSP1, HMGA1, LCP1, B3GAT1, and ZNF280C) that were significantly differentially expressed in PCOS granulosa cell transcriptomic datasets. Pathway enrichment analyses revealed their involvement in energy metabolism, cell proliferation and apoptosis, which highlights their potential roles in PCOS pathogenesis. A random forest-based diagnostic model showed high internal predictive performance, with an ROC AUC of 0.993; however, external validation yielded a lower AUC of 0.628, indicating limited generalizability and the need for further validation.
conclusionThese findings suggest that lactylation-related transcriptional signatures may serve as potential candidate biomarkers for the early detection of PCOS. However, because this study was based primarily on transcriptomic inference and did not directly measure lactylation modifications, the results should be interpreted as hypothesis-generating. Future studies should validate these biomarkers in larger clinical cohorts, primary granulosa cells, and through direct lactylation or proteomic assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.